SCHEMBL23767892

SCHEMBL23767892

O=C(O)Cc1ccc(-c2nccc(OCc3ccc(Cl)cc3F)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 3/20 0.46
KDM5B Q9UGL1 3/20 0.46
FFAR1 O14842 1/20 0.42
PTGER1 P34995 4/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
TBXA2R P21731 2/20 0.41
PTGS1 P23219 2/20 0.41
CYP2C19 P33261 2/20 0.41
PTGER3 P43115 2/20 0.41
PTGER2 P43116 2/20 0.41
XDH P47989 1/20 0.41
FFAR4 Q5NUL3 1/20 0.40
GLP1R P43220 6/20 0.39
KMO O15229 1/20 0.38
HPD P32754 1/20 0.38
KDM4C Q9H3R0 2/20 0.37
KDM4A O75164 1/20 0.37
KDM2B Q8NHM5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30124830 1.00 KDM5A (0.46) KDM5AKDM5BFFAR1PTGER1CYP1A2
SCHEMBL30080316 0.92 KDM5A (0.43) KDM5AKDM5BPTGER1CYP1A2CYP2C9
SCHEMBL23767891 0.92 KDM5A (0.43) KDM5AKDM5BPTGER1CYP1A2CYP2C9
SCHEMBL23767893 0.89 KDM5A (0.41) KDM5AKDM5BPTGER1CYP1A2CYP2C9
SCHEMBL25544407 0.88 PTGDR2 (0.48) KDM5AKDM5BFFAR1XDHFFAR4
SCHEMBL23767752 0.83 PTGER1 (0.46) FFAR1PTGER1CYP1A2CYP2C9TBXA2R
SCHEMBL30021781 0.83 PTGER1 (0.46) FFAR1PTGER1CYP1A2CYP2C9TBXA2R
SCHEMBL30080246 0.77 ALKBH1 (0.51) PTGER1CYP1A2PTGS1PTGER3PTGER2
SCHEMBL23767729 0.77 ALKBH1 (0.51) PTGER1CYP1A2PTGS1PTGER3PTGER2
SCHEMBL29141562 0.77 FFAR4 (0.43) KDM5AKDM5BFFAR1PTGER1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165846-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-01 US disclosed
US-20230165846-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-01 US disclosed
CN-115697999-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-02-03 CN disclosed
WO-2021160127-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2021-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165846-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR KDM5A 3899/4885KDM5B 3787/4885FFAR1 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.